ATE380019T1 - Abgabe eines nsaid aus embolischen mitteln - Google Patents

Abgabe eines nsaid aus embolischen mitteln

Info

Publication number
ATE380019T1
ATE380019T1 AT04713577T AT04713577T ATE380019T1 AT E380019 T1 ATE380019 T1 AT E380019T1 AT 04713577 T AT04713577 T AT 04713577T AT 04713577 T AT04713577 T AT 04713577T AT E380019 T1 ATE380019 T1 AT E380019T1
Authority
AT
Austria
Prior art keywords
polymer
nsaid
delivery
embolic agents
uterine
Prior art date
Application number
AT04713577T
Other languages
English (en)
Inventor
Andrew Lewis
Peter Stratford
Simon Leppard
Original Assignee
Biocompatibles Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocompatibles Uk Ltd filed Critical Biocompatibles Uk Ltd
Application granted granted Critical
Publication of ATE380019T1 publication Critical patent/ATE380019T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/603Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processing Of Solid Wastes (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
AT04713577T 2003-02-21 2004-02-23 Abgabe eines nsaid aus embolischen mitteln ATE380019T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03251075 2003-02-21

Publications (1)

Publication Number Publication Date
ATE380019T1 true ATE380019T1 (de) 2007-12-15

Family

ID=32892983

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04713577T ATE380019T1 (de) 2003-02-21 2004-02-23 Abgabe eines nsaid aus embolischen mitteln

Country Status (7)

Country Link
US (1) US20060057198A1 (de)
EP (1) EP1594472B1 (de)
AT (1) ATE380019T1 (de)
CA (1) CA2516736A1 (de)
DE (1) DE602004010492T2 (de)
ES (1) ES2298724T3 (de)
WO (1) WO2004073688A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
DE01918975T1 (de) * 2000-03-24 2006-04-13 Biosphere Medical, Inc., Rockland Mikrokügelchen zur aktiven Embolisierung
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7131997B2 (en) 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7053134B2 (en) 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US7449236B2 (en) 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7588825B2 (en) 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
WO2006013376A2 (en) * 2004-08-04 2006-02-09 Biocompatibles Uk Limited Drug delivery of a cox inhibitor from embolic agents
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
KR20140090270A (ko) 2005-05-09 2014-07-16 바이오스피어 메디칼 에스.에이. 마이크로스피어 및 비이온성 조영제를 사용하는 조성물 및 방법
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
US20080305176A1 (en) * 2006-01-24 2008-12-11 Biocompatibles Uk Limited Process For Loading Polymer Particles With Drug
EP2520287B1 (de) * 2006-02-10 2025-03-26 Boston Scientific Medical Device Limited Beladung von hydrophoben arzneimitteln in hydrophile polymer-abgabesysteme
US8062673B2 (en) 2006-04-11 2011-11-22 E I Du Pont De Nemours And Company Process for embolization using swellable and deformable microspheres
US8252339B2 (en) 2006-04-11 2012-08-28 Massachusetts Institute Of Technology Medical treatment applications of swellable and deformable microspheres
US7794755B2 (en) 2006-04-11 2010-09-14 E.I. Du Pont De Nemours And Company Process for preparation of swellable and deformable microspheres
US7838035B2 (en) 2006-04-11 2010-11-23 E. I. Du Pont De Nemours And Company Microsphere powder of high density, swellable, deformable, durable occlusion-forming microspheres
WO2009086076A2 (en) * 2007-12-28 2009-07-09 Boston Scientific Scimed, Inc. Particles for injection and processes for forming the same
JP2011519870A (ja) * 2008-05-21 2011-07-14 テイコク ファーマ ユーエスエー インコーポレーテッド 非ステロイド性抗炎症薬の経皮投与による月経困難症の治療
US8202531B2 (en) * 2008-07-23 2012-06-19 Warsaw Orthopedic, Inc. Drug depots having one or more anchoring members
US10071181B1 (en) 2015-04-17 2018-09-11 Teleflex Innovations S.À.R.L. Resorbable embolization spheres
WO2022047544A1 (en) * 2020-09-04 2022-03-10 IP Cornerstone Pty Ltd Minimally invasive treatment of osteoarthritis and other conditions
CN113855810A (zh) * 2021-09-22 2021-12-31 西安纳瑞工控科技有限公司 一种药用辅料聚苯乙烯磺酸钠微球及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012577A1 (en) * 1997-09-05 1999-03-18 Nycomed Imaging As Polymer particles made of polyvinyl alcohol and comprising a contrast agent for chemoembolization
FR2784580B1 (fr) * 1998-10-16 2004-06-25 Biosepra Inc Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci
US6562330B1 (en) * 1998-11-13 2003-05-13 Biocompatibles Limited Therapeutic use of polymers
EP1263803B1 (de) * 2000-03-13 2007-09-19 BioCure, Inc. Embolische zusammensetzungen

Also Published As

Publication number Publication date
DE602004010492D1 (de) 2008-01-17
EP1594472A1 (de) 2005-11-16
CA2516736A1 (en) 2004-09-02
US20060057198A1 (en) 2006-03-16
DE602004010492T2 (de) 2008-11-13
ES2298724T3 (es) 2008-05-16
EP1594472B1 (de) 2007-12-05
WO2004073688A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
ATE380019T1 (de) Abgabe eines nsaid aus embolischen mitteln
AR038375A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
ES2524556T3 (es) Composiciones farmacéuticas
Fichorova et al. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives
BRPI0513921A (pt) composição para cuidado oral, e, método para liberar um ativo para cuidado oral
Elavarasu et al. Host modulation by therapeutic agents
Schultzberg et al. Inflammation in the nervous system—physiological and pathophysiological aspects
Craft et al. Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats
Carlos et al. Protective effect of low-level laser therapy (LLLT) on acute zymosan-induced arthritis
ES2569477T3 (es) Combinación de un inhibidor de HDAC y un antimetabolito
UA27848C2 (uk) Лікарська форма, що перорально вводиться, для лікування центральних станів дефіциту допаміну
EA201000617A1 (ru) Комбинация, включающая производные пурина и другие соединения, и ее применение для лечения воспалительных и обструктивных заболеваний дыхательных путей
JP2011093898A (ja) 眼科組成物
WO2006013376A3 (en) Drug delivery of a cox inhibitor from embolic agents
Motavallian et al. Anti-inflammatory effects of alosetron mediated through 5-HT3 receptors on experimental colitis
Lorenz et al. IFN regulatory factor 4 controls post-ischemic inflammation and prevents chronic kidney disease
Huang et al. The mechanism of efferocytosis in the pathogenesis of periodontitis and its possible therapeutic strategies
Arab et al. Targeting inflammation and redox perturbations by lisinopril mitigates Freund’s adjuvant-induced arthritis in rats: Role of JAK-2/STAT-3/RANKL axis, MMPs, and VEGF
ES2516644T3 (es) Producto farmacéutico
Dutra et al. Inhibitor of PI3Kγ ameliorates TNBS‐induced colitis in mice by affecting the functional activity of CD4+ CD25+ FoxP3+ regulatory T cells
Sheng et al. Insights of efferocytosis in normal and pathological pregnancy
AR043418A1 (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor
RU2003100874A (ru) Болеутоляющие и противовоспалительные составы, содержащие ингибиторы циклооксигеназы-2
Bédouet et al. Tunable delivery of niflumic acid from resorbable embolization microspheres for uterine fibroid embolization
Jain et al. Design, characterization, and evaluation of meloxicam gel prepared by suspension and solution polymerization using solubility parameter as the basis for development

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties